Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan · Delayed Price · Currency is TWD 164.00
+1.00 (0.61%)
Jan 21, 2026, 1:30 PM CST
TPE:6919 Revenue
Caliway Biopharmaceuticals had revenue of 13.42M TWD in the quarter ending September 30, 2025, a decrease of -42.32%. This brings the company's revenue in the last twelve months to 34.99M, down -29.99% year-over-year. In the year 2024, Caliway Biopharmaceuticals had annual revenue of 44.43M with 14.13% growth.
Revenue (ttm)
34.99M
Revenue Growth
-29.99%
P/S Ratio
7,264.92
Revenue / Employee
n/a
Employees
n/a
Market Cap
254.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.43M | 5.50M | 14.13% |
| Dec 31, 2023 | 38.93M | 26.11M | 203.68% |
| Dec 31, 2022 | 12.82M | 481.00K | 3.90% |
| Dec 31, 2021 | 12.34M | 1.99M | 19.22% |
| Dec 31, 2020 | 10.35M | -8.30M | -44.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.00B |
| Ever Supreme Bio Technology | 1.01B |
| EirGenix | 936.18M |
| TaiMed Biologics | 607.22M |
| Tanvex BioPharma | 224.83M |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |